Price Alert

Agenus Inc. (AGEN)

NASDAQ: AGEN · Real-Time Price · USD

4.54

-0.09 (-1.94%)

At close: Aug 18, 2025, 3:59 PM

4.52

-0.55%

Pre-market: Aug 19, 2025, 05:02 AM EDT

-1.94% (1D)

Bid	4.09
Market Cap	144.82M
Revenue (ttm)	99.52M
Net Income (ttm)	-190.65M
EPS (ttm)	-7.06
PE Ratio (ttm)	-0.64
Forward PE	4.79
Analyst	Hold

Ask	4.73
Volume	223,951
Avg. Volume (20D)	1,253,222
Open	4.63
Previous Close	4.63
Day's Range	4.51 - 4.69
52-Week Range	1.38 - 7.34
Beta	1.62

About AGEN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AGEN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Agenus has released their quartely earnings on Aug 11, 2025:

Revenue of $25.7M misses estimates by $14.14M, with 9.32% YoY growth.

EPS of -1 misses estimates by -1.50, with 60.32% YoY growth.

Next Earnings Release

Agenus Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+19.26%

Agenus shares are trading higher after partner MiN... Unlock content with Pro Subscription

2 months ago

+12.6%

Agenus shares are trading higher after HC Wainwright & Co. and Baird raised their respective price targets on the stock.

News

1 week ago · zacks.com

Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates

Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.

1 week ago · businesswire.com

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2...

2 weeks ago · zacks.com

QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration

QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.

2 weeks ago · businesswire.com

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before th...

3 weeks ago · businesswire.com

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab i...

1 month ago · zacks.com

Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?

Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road...

1 month ago · zacks.com

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.

1 month ago · zacks.com

3 Top Earnings Acceleration Stocks to Buy for 2H25

Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.

1 month ago · businesswire.com

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

LEXINGTON, Mass.--(BUSINESS WIRE)-- #CancerCare--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved...

2 months ago · zacks.com

After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright

After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple mov...

Load More News